Table 3.

Multivariate analysis for post-relapse survival risk factors.

Factors	Model 1 (N=59 relapsed patients)		Model 2 (N=33 patients with persistent positive BCR-ABL)		Model 3 (N=22 patients with hematological relapse)
	Adjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
Disease status at transplant (AP)	15.9 (4.7–53.8)	<0.001	26.0 (6.3–107.7)	<0.0001	11.8 (2.8 – 50.3)	<0.001
Time to relapse <100 days	10.2 (3.2-32.8)	<0.001	5.3 (1.7– 16.6)	0.004	2.5 (0.77 – 7.9)	0.13
Pre-transplant TKI use	0.17 (0.04–0.67)	0.011	0.08 (0.02 – 0.34)	<0.001	0.14 (0.03 – 0.66)	0.012

Abbreviations: AP: Advanced phase; HR: hazard ratio; TKI: tyrosine kinase inhibitor